Does the media refer more to OCUL or BLTE?

In the previous week, Ocular Therapeutix had 9 more articles in the media than Belite Bio. MarketBeat recorded 14 mentions for Ocular Therapeutix and 5 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.20 beat Ocular Therapeutix's score of 0.08 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, LNTH or OCUL?

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.14 24.14 Ocular Therapeutix $52.06M 29.36 -$265.94M -$1.42 N/A

Does the media refer more to LNTH or OCUL?

In the previous week, Ocular Therapeutix had 3 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Ocular Therapeutix and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.23 beat Ocular Therapeutix's score of 0.08 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to OCUL or AMRX?

In the previous week, Ocular Therapeutix had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Ocular Therapeutix and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.51 beat Ocular Therapeutix's score of 0.08 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, LQDA or OCUL?

Liquidia has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 16.19 -$68.92M $1.37 20.91 Ocular Therapeutix $52.06M 29.36 -$265.94M -$1.42 N/A

Does the media favor LQDA or OCUL?

In the previous week, Liquidia had 17 more articles in the media than Ocular Therapeutix. MarketBeat recorded 31 mentions for Liquidia and 14 mentions for Ocular Therapeutix. Liquidia's average media sentiment score of 0.28 beat Ocular Therapeutix's score of 0.08 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 7 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Ocular Therapeutix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Ocular Therapeutix (OCUL) Competitors

$6.96 -0.33 (-4.53%)

Closing price 04:00 PM Eastern

Extended Trading

$7.06 +0.10 (+1.44%)

As of 07:33 PM Eastern

Compare

OCUL vs. BLTE, LNTH, AMRX, LQDA, and MANE

Should you buy Ocular Therapeutix stock or one of its competitors? Ocular Therapeutix's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Liquidia (LQDA), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ocular Therapeutix compare to Belite Bio?

Ocular Therapeutix (NASDAQ:OCUL) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

In the previous week, Ocular Therapeutix had 9 more articles in the media than Belite Bio. MarketBeat recorded 14 mentions for Ocular Therapeutix and 5 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.20 beat Ocular Therapeutix's score of 0.08 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Belite Bio has lower revenue, but higher earnings than Ocular Therapeutix. Belite Bio is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$52.06M	29.36	-$265.94M	-$1.42	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Ocular Therapeutix currently has a consensus price target of $25.29, suggesting a potential upside of 263.30%. Belite Bio has a consensus price target of $218.73, suggesting a potential upside of 37.08%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Belite Bio has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -579.10%. Belite Bio's return on equity of -11.84% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Belite Bio	N/A	-11.84%	-11.62%

Ocular Therapeutix has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

Summary

Ocular Therapeutix beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Ocular Therapeutix had 3 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Ocular Therapeutix and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.23 beat Ocular Therapeutix's score of 0.08 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.14
Ocular Therapeutix	$52.06M	29.36	-$265.94M	-$1.42	N/A

Lantheus has a net margin of 17.69% compared to Ocular Therapeutix's net margin of -579.10%. Lantheus' return on equity of 28.10% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Lantheus currently has a consensus price target of $108.11, suggesting a potential upside of 8.15%. Ocular Therapeutix has a consensus price target of $25.29, suggesting a potential upside of 263.30%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Lantheus beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Amneal Pharmaceuticals?

Ocular Therapeutix (NASDAQ:OCUL) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Ocular Therapeutix had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Ocular Therapeutix and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.51 beat Ocular Therapeutix's score of 0.08 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Amneal Pharmaceuticals has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Ocular Therapeutix presently has a consensus target price of $25.29, suggesting a potential upside of 263.30%. Amneal Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 3.45%. Given Ocular Therapeutix's higher probable upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Amneal Pharmaceuticals has a net margin of 5.05% compared to Ocular Therapeutix's net margin of -579.10%. Ocular Therapeutix's return on equity of -59.89% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$52.06M	29.36	-$265.94M	-$1.42	N/A
Amneal Pharmaceuticals	$3.02B	2.15	$72.06M	$0.49	41.43

Summary

Amneal Pharmaceuticals beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Liquidia has a net margin of 30.74% compared to Ocular Therapeutix's net margin of -579.10%. Liquidia's return on equity of 149.65% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

Liquidia has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	16.19	-$68.92M	$1.37	20.91
Ocular Therapeutix	$52.06M	29.36	-$265.94M	-$1.42	N/A

Liquidia has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Liquidia had 17 more articles in the media than Ocular Therapeutix. MarketBeat recorded 31 mentions for Liquidia and 14 mentions for Ocular Therapeutix. Liquidia's average media sentiment score of 0.28 beat Ocular Therapeutix's score of 0.08 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	7 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Ocular Therapeutix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Liquidia presently has a consensus price target of $83.69, suggesting a potential upside of 192.22%. Ocular Therapeutix has a consensus price target of $25.29, suggesting a potential upside of 263.30%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Liquidia beats Ocular Therapeutix on 12 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Veradermics?

Ocular Therapeutix (NASDAQ:OCUL) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Ocular Therapeutix had 14 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Ocular Therapeutix and 0 mentions for Veradermics. Ocular Therapeutix's average media sentiment score of 0.08 beat Veradermics' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Overall Sentiment
Ocular Therapeutix	Neutral
Veradermics	Neutral

59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Veradermics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -579.10%. Veradermics' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Veradermics	N/A	N/A	N/A

Veradermics has lower revenue, but higher earnings than Ocular Therapeutix. Veradermics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$52.06M	29.36	-$265.94M	-$1.42	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Ocular Therapeutix currently has a consensus target price of $25.29, indicating a potential upside of 263.30%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 31.71%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, research analysts clearly believe Ocular Therapeutix is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Ocular Therapeutix beats Veradermics on 10 of the 14 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCUL vs. The Competition

Export

Metric	Ocular Therapeutix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60B	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.77%
P/E Ratio	-4.90	794.62	273.67	26.04
Price / Sales	29.36	757.46	612.51	90.64
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	2.27	10.46	10.92	6.30
Net Income	-$265.94M	$2.83B	$3.50B	$361.43M
7 Day Performance	-27.88%	-1.65%	-2.11%	-1.67%
1 Month Performance	-36.15%	-5.77%	-6.34%	-3.94%
1 Year Performance	-37.07%	-3.80%	8.81%	2.77%

Ocular Therapeutix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCUL Ocular Therapeutix	2.701 of 5 stars	$6.96 -4.5%	$25.29 +263.3%	-34.0%	$1.60B	$52.06M	N/A	325	News Coverage Analyst Forecast
BLTE Belite Bio	3.3175 of 5 stars	$165.93 -0.8%	$218.73 +31.8%	+121.7%	$6.74B	N/A	N/A	41
LNTH Lantheus	3.2165 of 5 stars	$99.74 flat	$108.11 +8.4%	+93.0%	$6.51B	$1.54B	24.09	1,193	Positive News
AMRX Amneal Pharmaceuticals	3.1145 of 5 stars	$20.50 +3.7%	$21.00 +2.4%	+93.4%	$6.31B	$3.02B	41.84	8,500	Analyst Forecast
LQDA Liquidia	4.1057 of 5 stars	$73.67 +7.7%	$98.08 +33.1%	+26.9%	$6.13B	$158.32M	53.77	216	Trending News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCUL) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Competitors

OCUL vs. BLTE, LNTH, AMRX, LQDA, and MANE

How does Ocular Therapeutix compare to Belite Bio?

Summary

How does Ocular Therapeutix compare to Lantheus?

Summary

How does Ocular Therapeutix compare to Amneal Pharmaceuticals?

Summary

How does Ocular Therapeutix compare to Liquidia?

Summary

How does Ocular Therapeutix compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Competitors

OCUL vs. BLTE, LNTH, AMRX, LQDA, and MANE

How does Ocular Therapeutix compare to Belite Bio?

Does the media refer more to OCUL or BLTE?

Do institutionals & insiders hold more shares of OCUL or BLTE?

Which has higher valuation & earnings, OCUL or BLTE?

Do analysts prefer OCUL or BLTE?

Is OCUL or BLTE more profitable?

Which has more risk and volatility, OCUL or BLTE?

Summary

How does Ocular Therapeutix compare to Lantheus?

Do institutionals and insiders believe in LNTH or OCUL?

Does the media refer more to LNTH or OCUL?

Which has preferable earnings and valuation, LNTH or OCUL?

Is LNTH or OCUL more profitable?

Which has more risk and volatility, LNTH or OCUL?

Do analysts recommend LNTH or OCUL?

Summary

How does Ocular Therapeutix compare to Amneal Pharmaceuticals?

Do institutionals & insiders believe in OCUL or AMRX?

Does the media refer more to OCUL or AMRX?

Which has more risk & volatility, OCUL or AMRX?

Do analysts recommend OCUL or AMRX?

Is OCUL or AMRX more profitable?

Which has stronger valuation and earnings, OCUL or AMRX?

Summary

How does Ocular Therapeutix compare to Liquidia?

Is LQDA or OCUL more profitable?

Which has preferable earnings & valuation, LQDA or OCUL?

Which has more volatility & risk, LQDA or OCUL?

Do institutionals and insiders hold more shares of LQDA or OCUL?

Does the media favor LQDA or OCUL?

Do analysts recommend LQDA or OCUL?

Summary

How does Ocular Therapeutix compare to Veradermics?

Does the media prefer OCUL or MANE?

Do insiders and institutionals believe in OCUL or MANE?

Is OCUL or MANE more profitable?

Which has preferable earnings & valuation, OCUL or MANE?

Do analysts rate OCUL or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools